Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Alcon to buy Aerie Pharmaceuticals for $770M

Eye care drug company Alcon and Aerie Pharmaceuticals have entered a definitive merger agreement through which Alcon will acquire Aerie for $770 million.

The acquisition will give Alcon access to Aerie’s marketed fixed-dose kinase inhibitors, Rocklatan and Rhopressa, as well as other clinical and preclinical ophthalmic pharmaceutical products. In exchange, Aerie will receive $15.25 per share, a premium of 37% to the last closing price.

Alcon’s CEO David Endicott says the company is looking forward to joining forces. “Aerie is a natural fit with on-market and pipeline products, and R&D capabilities that offer the infrastructure needed to expand our ophthalmic pharmaceutical presence. As we continue to broaden our portfolio across glaucoma, retina, and ocular surface disease, we are excited to help even more patients see brilliantly.”

Most recently, Aerie’s financial guidance for its total glaucoma franchise net product revenue totalled $130-$140 million for 2022. Alcon, based in Switzerland, profited $8.2 billion in 2021 with a net income of $1.1 billion.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025